The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AYTU | +56.83% | -98.73% | -58.21% | -100% |
| S&P | +14.39% | +76.41% | +12.02% | +231% |
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.
No news articles found for Aytu BioPharma.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $15.17M | -6.5% |
| Gross Profit | $9.10M | -7.8% |
| Gross Margin | 59.99% | -0.8% |
| Market Cap | $26.49M | 153.4% |
| Market Cap / Employee | $319.15K | 0.0% |
| Employees | 83 | -18.6% |
| Net Income | -$10,584.00K | -1691.6% |
| EBITDA | -$1,085.00K | -212.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $30.03M | 47.2% |
| Accounts Receivable | $30.92M | 21.7% |
| Inventory | 8.7 | -21.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $10.97M | -1.1% |
| Short Term Debt | $11.13M | 83.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -20.62% | -16.0% |
| Return On Invested Capital | -59.60% | -5.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $3.66M | 26.2% |
| Operating Free Cash Flow | $3.68M | 26.5% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.24 | 0.39 | 0.89 | 1.11 | 217.32% |
| Price to Sales | 0.14 | 0.22 | 0.57 | 0.42 | 98.59% |
| Price to Tangible Book Value | -0.39 | -0.97 | -0.73 | -1.41 | 188.63% |
| Price to Free Cash Flow TTM | 1.94 | 27.17 | - | ||
| Enterprise Value to EBITDA | 3.80 | 3.51 | -46.20 | -16.75 | -244.12% |
| Free Cash Flow Yield | 51.6% | 3.7% | - | ||
| Return on Equity | 3.3% | -60.8% | -50.2% | -109.2% | 504.70% |
| Total Debt | $22.52M | $22.94M | $28.40M | $22.10M | 28.94% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
